Tara Biosystems, Inc., a NYC-based vitro human biology company, raised $10m in Series A2 financing.
Backers included new investors OMX Ventures, Merieux Equity Partners, and LifeForce Capital and current investors Alexandria Venture Investments, Partnership Fund for New York City, Trancos Ventures, DEFTA Partners, New York Ventures and Tachyon Ventures. In conjunction with the funding, Daniel Fero, Ph.D., Managing Director of OMX Ventures, joined TARA’s Board of Directors.
The company intends to use the funds to scale its cardiac tissue engineering platform technology and advance its drug discovery programs.
Founded in 2014 and led by Misti Ushio, Ph.D., Chief Executive Officer, Tara develops in vitro biology with a focus on translational cardiac tissue models. Its induced pluripotent stem cell derived human cardiac tissue is a versatile drug discovery and development model that enables researchers to evaluate both drug safety and efficacy endpoints in vitro to quickly generate highly translatable data in a preclinical setting. The platform allows for broad-based phenotypic analysis of healthy, gene-edited, patient-derived, and drug-induced models of human cardiac disease at scale and captures physiologic endpoint measurements including contractility, electrophysiology, calcium signaling, structure, as well as genomic, proteomic, and metabolic profiles.